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Abstract 
We present a retrospective analysis on a cohort of low grade, node negative patients 
demonstrating that HER2 status significantly impacts on survival in this otherwise 
very good prognostic group. Our results provide support for the use of adjuvant 
trastuzumab in patients who are typically classified as very good prognosis, not 
routinely offered standard chemotherapy, and as such do not fit current prescribing 
guidelines for trastuzumab.  
 
Keywords 
HER2, breast cancer, trastuzumab 
 Background 
HER2 amplification has become the prototype biomarker for translation of a 
laboratory discovery through to development of a highly successful individualised 
chemotherapy agent. Slamon et al (Slamon et al., 1987) established HER2 as a poor 
prognostic marker for survival in breast cancer and developed a monoclonal antibody, 
trastuzumab, targeted to HER2 as a novel therapy for breast cancer patients. More 
recently, randomised trials have shown a clinical benefit of trastuzumab with 
significant overall survival benefit in early breast cancer over observation alone after 
chemotherapy (Joensuu et al., 2006; Romond et al., 2005; Smith et al., 2007). As a 
resuslt, trastuzumab has been introduced into routine clinical practice in the UK for 
HER2 positive patients who have finished their standard adjuvant treatment. Current 
Scottish and NICE guidelines parallel the HERA trial entry criteria where 
trastuzumab is offered only to those patients who have already received standard 
chemotherapy regimes as part of their treatment regime.  
However, there remains a small subset HER2 positive patients who are low grade and 
node negative who are currently ineligible for trastuzumab treatment as clinically they 
have deemed to have no requirement for standard adjuvant chemotherapy. In our 
region approximately 25% of HER2 patients are not offered Herceptin as they are 
deemed to be ‘low risk’(personal communication). A recent review (Dinh et al., 2008) 
outlines the controversy and current lack of trial evidence for use of trastuzumab in 
small, node-negative cancers with none of the randomised clinical trials having 
addressed this small but important group of patients. 
Deleted: the 
Our study analyses a retrospective cohort of tumours traditionally classed by way of 
grade and nodal status as ‘low risk’, to assess if HER2 positivity impacts on survival 
in this otherwise very good prognostic group. 
 
Methods 
Patients 
We have a large cohort (n=1351) of breast cancers diagnosed between 1980-2002 
with full follow-up (median 6.5yrs) and clinicopathological details. Tissue specimens 
from these cancers had been used to create TMAs (tissue microarray technology) for 
research purposes. From this database we wished to identify a group of patients who 
would classically be identified as ‘low risk’. We selected all node negative, grade 1 or 
2 cancers (n=362) for further analysis.  
HER2 status assessment 
HER2 status was identified using currently applicable clinical methodology (Bartlett 
et al., 2003). Dako Herceptest was used to quantify immunohistochemical staining. 
All 3+ (high intensity) staining specimens were considered positive. All 2+ (moderate 
staining) specimens underwent FISH analysis and those who demonstrated HER2 
amplification were also classed as positive. 
Analysis 
SPSS (v15) was used to plot Kaplan-Meier survival curves using breast cancer 
specific death as an outcome endpoint. Cox Regression analysis was performed to 
assess hazard ratios for the impact of HER2 status on breast cancer specific death in 
the subcategories split on ER status, age of patient and size of tumour. 
 
Results 
Patient characteristics (table 1) 
We selected all node negative, grade 1 or 2 cancers (n=362) from our original cohort. 
This group were 90% ER positive, with 71% smaller than 20mm. 80% were aged over 
50 and 10% received chemotherapy and 91% received endocrine therapy (tamoxifen).  
 
HER2 status and survival 
6.1 % of cases were HER2 positive. The overall hazard ratio (HR) for HER2 
positivity was 5.65 (95% CI 2.4-13.1, p < 0.001) giving 5yr breast cancer specific 
survival rates of 68% compared to 96% for the HER2 negative group (figure 1). This 
reduction in survival in HER2 positive cases persisted when patients were split into 
subgroups by ER status, tumour size and age (table 2). 
 
Discussion 
Our results suggest that no HER2 positive patient should be classed as ‘low risk’. 
There have been conflicting reports on the impact of HER2 status in good prognostic 
groups in the literature. Some have shown similar results in node negative patients 
(Andrulis et al., 1998; Schmidt et al., 2005; Paik et al., 1990; Harbeck et al., 1999; 
Kallioniemi et al., 1991; Press et al., 1997; Quenel et al., 1995) even with small 1-
10mm tumours (Joensuu et al., 2003) or with lower grade (Paik et al., 1990). Other 
papers have not confirmed this, (Ko et al., 2007; Richner et al., 1990; Rosen et al., 
1995) although care must be undertaken when interpretating older studies that may 
not use currently accepted methods of HER2 testing or have underpowered studies. 
Our results are in keeping with those from HERA trial that suggested that patients 
with the best prognosis tumours (node negative and size 1-2cm) had benefit similar to 
the overall cohort (Untch et al., 2008). We suggest this reinforces the importance of 
having HER2 results available in MDT on these patients to enable clinicians to make 
informed decisions on their outlook and treatment options. 
The persistence of a reduction in survival in our HER2 positive /ER positive subgroup 
despite endocrine therapy is in keeping with the recent trans-ATAC and BIG1-98 
analysis based on HER2 status (Ranganathan et al., 2007) (Rasmussen et al., 2008) 
and demonstrated that we cannot not rely solely on adjuvant endocrine therapy 
(tamoxifen or aromatase inhibitor) in these largely ER positive patients. 
 
Sub analysis was not performed on tumours less than 10mm in size due to the small 
number of tumours falling into the subgroup. However it may be argued that tumour 
size is a marker of the timeline over which the cancer is diagnosed, rather than a true 
reflection of the abnormal biology driving the cancer and hence in the case of HER2 
positive disease should not be a criteria for deciding to withhold adjuvant treatment. 
In conclusion, these results provide support for the rationale of using of adjuvant 
trastuzumab in this subgroup of patients who are typically classified as very good 
prognosis, may not be routinely offered standard chemotherapy, and as such do not fit 
current prescribing guidelines for trastuzumab. A clinical trial to assess the benefit of 
adjuvant trastuzumab within this group of HER2 patients would resolve this. Whether 
trastuzumab would be effective alone in these patient (without the potential side 
effects of standard chemotherapy regimes) deserves investigation. The combination of 
hormonal therapy and trastuzumab may be particularly attractive in ER positive 
patients where trastuzumab may overcome the crosstalk between the HER and ER 
receptors which is likely responsible for the reduced efficacy of hormonal therapy in 
this group. 
number valid %
1 114 31.5
2 248 68.5
Positive 283 89.6
Negative 33 10.4
unknown 49
Positive 340 93.9
Negative 22 6.1
ductal 286 79.2
lobular 40 11.1
other 35 9.7
unknown 1
T1 (<20mm) 230 71.2
T2 (20-50mm) 93 28.8
unknown 41
Age <50 years 71 19.6
>50 years 161 44.5
unknown 130 35.9
Chemotherapy yes 33 10.2
no 290 89.8
unknown 44
yes 296 91.9
no 26 8.1
unknown 45
Table 1: Clinicopathological details
Endocrine 
(mainly 
tamoxifen)
Histological 
Type
Size
Grade
ER status
HER2 status
number in 
group Sig. Hazard Ratio
HER2 pos HER2neg Lower Upper
Whole cohort 362 7/22 26/340 0.000 5.65 2.43 13.12
ER positive 283 3/13 17/270 0.010 5.07 1.47 17.51
ER negative 33 3/6 6/27 0.049 4.41 1.01 19.27
Age<50 71 2/8 3/63 0.036 8.10 1.14 57.56
Age 50-65 161 3/9 10/152 0.004 6.73 1.84 24.65
Age>65 130 2/5 13/125 0.033 5.09 1.14 22.66
Size<20mm 230 5/16 9/214 0.000 8.99 3.00 26.96
size>20mm 93 2/5 12/88 0.016 6.93 1.44 33.49
Table 2: Subgroup Hazard Ratio analysis (Cox regression )
Events 95.0% CI 
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